Compare Medpace Holdings Inc (MEDP) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Advanced Drainage Systems Inc — how do they compare? Medpace Holdings Inc trades at $614.07 (market cap $16.82B), while Advanced Drainage Systems Inc trades at $126.22 (market cap $9.52B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Advanced Drainage Systems Inc for 43 Days on average.
| MEDP | WMS | |
|---|---|---|
Market Cap | $16.82B | $9.52B |
Volume | 223,093 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $630.19 | $175.38 |
52-Week Low | $393.42 | $125.33 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | $16.44B | $11.12B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
WMS (Advanced Drainage Systems) trades at $124.92, down 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news includes the release of its 2026 Sustainability Report and a declared dividend of $0.20 per share payable in September 2026.
The outlook is supported by consistent earnings beats and analyst consensus pointing to significant upside with a $188.70 price target. However, a projected negative net cash flow of -$473M for 2026 and bearish technical indicators present near-term risks. Investor sentiment is mixed amid institutional buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
